Jet2 summer bookings rise as easing Middle East tensions support demand
Travel demand is showing firmer momentum for Jet2 as holidaymakers regain confidence in booking summer trips. The UK company says booked-to-date passengers for the summer season are up 7.1%, while its annual pretax profit declines from the previous year.
Highlights
- Jet2 reports booked-to-date summer passengers up 7.1% following easing geopolitical tensions boosting recent travel demand.
- Profit before taxation for the year ended March 31 fell 7% to £551 million, despite improved summer booking momentum.
- Industry pressures from higher costs and weak consumer confidence persist, but peace negotiations around the Iran war are supporting the demand outlook for Jet2 and sector peers.
Summer booking momentum and annual results
As reported by Reuters, Jet2 says on Wednesday that easing geopolitical tensions have driven strong bookings in recent weeks, helping lift booked-to-date summer passengers by 7.1%. The company operates flights and package holidays in the UK travel market.For the year ended March 31, Jet2 posts profit before taxation of 551 million pounds, down 7% from 593.2 million pounds a year earlier. The figures indicate that stronger recent booking trends come alongside softer full-year earnings.
Travel sector pressures and demand outlook
The global aviation and leisure industry is contending with higher costs and weak consumer confidence linked to the Iran war. Peace negotiations aimed at ending the war are giving some holidaymakers more confidence to proceed with travel plans.For Jet2, the improvement in summer bookings suggests that easing regional tensions are starting to support demand in the holiday travel sector. That trend is important for airlines and package operators as they manage pricing, costs and consumer sentiment during the peak summer season.
Our earlier coverage of JetBlue Airways (JBLU) focused on how operational disruptions and flight cancellations at Orlando weighed on near-term revenue expectations and investor sentiment. We also noted that the stock was trading below key short-term moving averages, with mixed momentum indicators pointing to elevated volatility and a range-bound outlook unless operations stabilize.
Latest Royalty Pharma News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
